• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Armed with a batch of positive biomarker data, a rare disease player reaps $88M for the...

cafead

Administrator
Staff member
  • cafead   Feb 20, 2020 at 10:42: AM
via Omega Funds and Abingworth teamed up to lead an $88 million round for Spruce, which is primarily focused on developing tildacerfont to treat classic congenital adrenal hyperplasia.

article source
 

<